title: Angiogenesis as a therapeutic target in urothelial carcinoma.
abstract: In the last few years, angiogenesis has confirmed its critical role in the development of malignant neoplasms. Antiangiogenic drugs, mainly bevacizumab, sorafenib, or sunitinib, are currently approved in a wide number of tumor types, such as breast, colorectal, liver, or kidney cancer, and have changed dramatically the evolution of our patients. Unfortunately, in urothelial carcinoma, which is a very common neoplasm, antiangiogenic agents are still in a very preliminary phase of clinical research. In this study, we focus on the biological basis of angiogenesis in urothelial tumors, its influence in the prognosis of these malignancies, and the available evidence about the use of antiangiogenic drugs in urothelial carcinoma.
authors: Department of Medical Oncology, University Hospital La Paz, Madrid, Spain. alvaropintomarin@gmail.com
authors: Alvaro
authors: A
authors: Pinto
authors: Andrés
authors: A
authors: Redondo
authors: Pilar
authors: P
authors: Zamora
authors: Beatriz
authors: B
authors: Castelo
authors: Enrique
authors: E
authors: Espinosa
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates / Q000494:pharmacology; D000068258:Bevacizumab; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D020782:Matrix Metalloproteinases / Q000502:physiology; D020360:Neoadjuvant Therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D051381:Rats; D000077157:Sorafenib; D000077210:Sunitinib; D015996:Survival Rate; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000098:blood supply / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000098:blood supply / Q000188:drug therapy; D019459:Urothelium / Q000098:blood supply / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000502:physiology; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000502:physiology; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; D040281:Vascular Endothelial Growth Factor Receptor-1; D020782:Matrix Metalloproteinases; D000077210:Sunitinib